Docket No. PP022095.0003

Declaration For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

COMBINATION VACCINES WITH LOW DOSE OF HIB CONJUGATE

the specification of	which		
(check one)			
☐ is attached here	eto.		
was filed on 14	March 2005	as United States Application No.	or PCT International
	nber PCT/IB2005/00092		
• •	ed on 15 September 200		
		(if applicable)	
_		nderstand the contents of the above in mendment referred to above.	dentified specification,
1.56, including for between the filing do continuation-in-part. I hereby claim fore application(s) for p	continuation-in-part a ate of the prior applica application. eign priority benefits ure atent, inventor's or please.	ation which is material to patentability pplications, material information whitions and the national or PCT internations and the national or PCT internations and breeder's rights certificate(s), or	ch became available tional filing date of the 365(b) of any foreign 365(a) of any PCT
America, listed belo patent or inventor's	w and have also identi or plant breeder's righ	ed at least one country other than fied below, by checking the box, any ts certificate(s), or any PCT internation which priority is claimed.	foreign application for
Prior Foreign Applic	eation(s)		Priority Claimed
0405787.3	GB	15 March 2004	\S
(Number)	(Country)	(Day/Month/YearFiled)	
/Alouge le colo			\boxtimes
(Number)	(Country)	(Day/Month/YearFiled)	
(Number)	(Country)	(Day/Month/YearFiled)	
O.SP. 01 (0.9E) (Modified)		DOOA/DEVICE Balance of Transfer only O	

N/A		
(Application Serial No.)	(Filing Date)	
(Application Serial No.)	(Filing Date)	
(Application Serial No.)	(Filing Date)	
nereby claim the benefit under 3 ection 365(c) of any PCT Internat sofar as the subject matter of ea nited States or PCT International	tional application designating ach of the claims of this app I application in the manner p	any United States application(s), on the United States, listed below and blication is not disclosed in the price rovided by the first paragraph of 3
nereby claim the benefit under 3 ection 365(c) of any PCT International sofar as the subject matter of eachited States or PCT International S.C. Section 112, I acknowledge fice all information known to meetion 1.56 which became available PCT International filing date of the	tional application designating ach of the claims of this application in the manner pethe duty to disclose to the late to be material to patentable between the filing date of	the United States, listed below and blication is not disclosed in the price
nereby claim the benefit under 3 ection 365(c) of any PCT International sofar as the subject matter of eachited States or PCT International S.C. Section 112, I acknowledge fice all information known to meetion 1.56 which became available	tional application designating ach of the claims of this application in the manner pethe duty to disclose to the late to be material to patentable between the filing date of	the United States, listed below and blication is not disclosed in the price rovided by the first paragraph of 3 United States Patent and Trademark bility as defined in Title 37, CFI
nereby claim the benefit under 3 ection 365(c) of any PCT International sofar as the subject matter of eachited States or PCT International S.C. Section 112, I acknowledge fice all information known to nection 1.56 which became available PCT International filing date of the N/A	tional application designating ach of the claims of this application in the manner plethe duty to disclose to the ne to be material to patentable between the filing date of is application:	the United States, listed below and plication is not disclosed in the price rovided by the first paragraph of 3 United States Patent and Trademark ability as defined in Title 37, CFI the prior application and the national (Status)

willful false statements may jeopardize the validity of the application or any patent issued thereon.

Form PTO-SB-01 (6-95) (Modified)

CONTORNI, Mario Sole or first inventor's signature	Date
Sole of hist inventor s signature	Date
Residence	
Citizenship (taly	
Post Office Address Lo Novartis Vaccines and Diagnostics Inc, P.O. Box 8097, Emeryvill	le, California 94662-8097, US
full name of second inventor, if any	•
Second inventor's signature	Date
	Date
Residence	
Ditizenship	
Post Office Address	
•	
full name of third inventor, if any	
	Date
Third inventor's signature	Date
Third inventor's signature Residence	Date
Third inventor's signature Residence Citizenship	
Full name of third inventor, if any Third inventor's signature Residence Citizenship Post Office Address	
Third inventor's signature Residence Citizenship	
Third inventor's signature Residence Citizenship	
Third inventor's signature Residence Citizenship Post Office Address	
Third inventor's signature Residence Citizenship Post Office Address Full name of fourth inventor, if any	
Third inventor's signature Residence Citizenship Post Office Address Full name of fourth inventor, if any Fourth inventor's signature	
Third inventor's signature Residence Ditizenship Post Office Address Full name of fourth inventor, if any Fourth inventor's signature Residence	
Third inventor's signature Residence Citizenship	